Literature DB >> 23190161

Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.

B M Nørgård1, J Nielsen, N Qvist, K O Gradel, O B Schaffalitzky de Muckadell, J Kjeldsen.   

Abstract

BACKGROUND: A possible negative role of pre-operative use of antitumour necrosis factor-alpha (anti-TNF-α) agents on post-operative outcomes in Crohn's disease (CD) patients is still debated. AIM: To examine the impact of pre-operative anti-TNF-α agents on post-operative outcomes 30 and 60 days after CD surgery in a nationwide Danish cohort. Outcomes were death, reoperation, anastomosis leakage, intra-abdominal abscess and bacteraemia.
METHODS: We identified all patients having surgical procedures from 1 January 2000 to 31 December 2010 (n = 2293). Patients were classified according to use of anti-TNF-α agents within 12 weeks before surgery (exposed) or not (unexposed). Outcomes were obtained from nationwide registries and a bacteraemia registry. Sub-analyses were performed for bacteraemia and for impact of pre-operative timing of anti-TNF-α agents.
RESULTS: Among surgical procedures for CD, 214 were exposed and 2079 were not. We found no increased relative risks of death or abscess drainage 30 or 60 days after follow-up. Among exposed, 7.5% had a reoperation within 30 days vs. 8.6% among unexposed, adjusted odds ratio (OR) = 0.92, 95% confidence interval (CI): 0.52-1.63. Among exposed, 3.8% had an anastomosis leakage within 30 days after surgery vs. 2.8% among unexposed, adjusted OR = 1.33, 95% CI: 0.59-3.02. No further cases of anastomosis leakages appeared within 60 days. Sub-analyses indicated no increased risk of bacteraemia after 30 days and no increased risks when anti-TNF-α agents were given ≤14 days before surgery.
CONCLUSION: We found no significantly increased relative risks of post-operative complications after use of anti-TNF-α agents either 12 weeks or ≤14 days before surgery for Crohn's disease.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190161     DOI: 10.1111/apt.12159

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

Review 1.  Positioning therapy for Crohn's disease.

Authors:  Alexandra Gutierrez; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2014

Review 2.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

Review 3.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

4.  Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.

Authors:  Takayuki Yamamoto; Antonino Spinelli; Yasuo Suzuki; Rogerio Saad-Hossne; Fabio Vieira Teixeira; Idblan Carvalho de Albuquerque; Rodolff Nunes da Silva; Ivan Folchini de Barcelos; Ken Takeuchi; Akihiro Yamada; Takahiro Shimoyama; Lorete Maria da Silva Kotze; Matteo Sacchi; Silvio Danese; Paulo Gustavo Kotze
Journal:  United European Gastroenterol J       Date:  2015-08-06       Impact factor: 4.623

5.  Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  YuJie Qiu; ZiCheng Zheng; Gang Liu; XinYu Zhao; AnQi He
Journal:  United European Gastroenterol J       Date:  2019-09-30       Impact factor: 4.623

Review 6.  Perioperative Considerations in Crohn Disease and Ulcerative Colitis.

Authors:  T Paul Nickerson; Amit Merchea
Journal:  Clin Colon Rectal Surg       Date:  2016-06

7.  Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis.

Authors:  Peter Waterland; Thanos Athanasiou; Heena Patel
Journal:  World J Gastrointest Surg       Date:  2016-03-27

Review 8.  Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Junzo Shimizu; Hiroki Ohge; Seiji Haji; Toru Mizuguchi; Yasuhiko Mohri; Chizuru Yamashita; Yuichi Kitagawa; Katsunori Suzuki; Motomu Kobayashi; Masahiro Kobayashi; Fumie Sakamoto; Masahiro Yoshida; Toshihiko Mayumi; Koichi Hirata; Yoshio Takesue
Journal:  Surg Today       Date:  2020-04-10       Impact factor: 2.549

9.  Glasgow prognostic score is a practical predictive index for postoperative intra-abdominal septic complications after bowel resection in Crohn's disease patients.

Authors:  Yibin Zhu; Haili Xu; Wei Liu; Weilin Qi; Xiaoyan Yang; Lingna Ye; Qian Cao; Wei Zhou
Journal:  Int J Colorectal Dis       Date:  2018-04-23       Impact factor: 2.571

Review 10.  Surgical Considerations in the Treatment of Small Bowel Crohn's Disease.

Authors:  Lillias Holmes Maguire; Karim Alavi; Ranjan Sudan; Paul E Wise; Andreas M Kaiser; Liliana Bordeianou
Journal:  J Gastrointest Surg       Date:  2016-12-13       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.